Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BTX A51

Next Previous
Drug Profile

BTX A51

Alternative Names: BTX-A51; PHM®-A51 PROTACs

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioTheryX; Edgewood Oncology
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Cyclohexanes; Cyclopropanes; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Casein kinase I inhibitors; Cyclin-dependent kinase 9 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer
  • Phase I Liposarcoma
  • No development reported Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 28 Apr 2025 Pharmacodynamics data from a phase I trial in Liposarcoma released by Edgewood Oncology
  • 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical study in Liposarcoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 30 Sep 2024 Phase-I clinical trials in Liposarcoma (Metastatic disease, recurrent, Second-line therapy or greater) in USA (PO) (NCT06414434)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top